Stemline Therapeutics, Inc.
STML
STML was delisted on the 9th of June, 2020.
75 hedge funds and large institutions have $119M invested in Stemline Therapeutics, Inc. in 2017 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 33 increasing their positions, 15 reducing their positions, and 14 closing their positions.
120% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 15
104% more call options, than puts
Call options by funds: $2.41M | Put options by funds: $1.18M
43% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 14
14% more capital invested
Capital invested by funds: $104M → $119M (+$14.7M)
1% more funds holding
Funds holding: 74 → 75 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$11M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$9.69M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$8.29M |
| 4 |
Axa
Paris,
France
|
+$3.96M |
| 5 |
IBT
International Biotechnology Trust
London,
United Kingdom
|
+$3.01M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$2.61M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$1.81M |
| 3 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$1.01M |
| 4 |
VMI
VHCP Management II
New York
|
-$801K |
| 5 |
Renaissance Technologies
New York
|
-$701K |
STML Hedge Fund Activity: Q1 2017 in Review
75 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Stemline Therapeutics, Inc. (STML) for Q1 2017, worth a combined $119M — up 14% from $104M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new STML positions and 14 closed out — a net gain of 6 holders — while 33 added to existing stakes and 15 trimmed.
The largest buyer was BlackRock, adding an estimated $11M. The largest seller was Candriam SCA, exiting entirely with an estimated $2.61M sold.
- 75 institutional investors held Stemline Therapeutics, Inc. (STML) as of Q1 2017, up from 74 in Q4 2016.
- Funds reported $119M of Stemline Therapeutics, Inc. stock for Q1 2017, up 14% quarter-over-quarter.
- 20 funds opened new Stemline Therapeutics, Inc. positions in Q1 2017 and 14 closed out, a net change of +6 holders.
- The largest Stemline Therapeutics, Inc. buyer in Q1 2017 was BlackRock, an estimated $11M added.
- The largest Stemline Therapeutics, Inc. seller in Q1 2017 was Candriam SCA, an estimated $2.61M sold.
Based on aggregated 13F filings for Q1 2017.